Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGL-270
- Development stage
- Phase 1
- Lead developer
- Regenelead Therapies
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RGL-270 (also known as HRXG-K-1939) is a personalized cancer vaccine (PCV) developed by Shanghai Regenelead Therapies in collaboration with Jiangsu Hengrui Pharmaceuticals. It consists of lipid nanoparticle (LNP)-encapsulated mRNA that encodes patient-specific tumor neoantigens identified through a proprietary screening algorithm. The vaccine is designed to induce a robust, tumor-specific immune response by activating T cells against somatic mutations unique to the patient's tumor. RGL-270 is primarily being investigated as an adjuvant therapy in combination with immune checkpoint inhibitors, such as the anti-PD-L1 antibody adebrelimab, for the treatment of resectable pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), as well as in advanced solid tumors.
- Other names
- personalized cancer vaccinePCV
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on RGL-270.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGL-270.